Back
 OJD  Vol.8 No.3 , August 2019
Ketamine Infusion (KI) in Treatment Resistant Depression (TRD): Retrospective Clinical Data Analysis
Abstract: Objective: The aim of this paper is to present the clinical data analysis results from a service delivering ketamine infusion, repetitive transcranial magnetic stimulation (rTMS) and electroconvulsive therapy for people with treatment resistant depression (TRD). Methods: The study was a retrospective investigation of routinely collected data on patients receiving ketamine infusion between 2017 and 2019. Measures used were the clinician-rated Clinical Global Impression (CGI) and self-reported Beck Depression Inventory (BDI) and Quick Inventory of Depressive Symptomatology (QIDS-SR). The outcome data of 28 patients with TRD were analysed. A minimum course of treatment was defined as three ketamine infusions. Results: Response combined with partial response, response, and remission rates respectively were 42.3%, 23.1% and 4.2% for the BDI; 18.2%, 9.1% and 0% for the QIDS-SR; 50%, 18.2% and 4.6% for the CGI. There was a statistically significant improvement on the BDI with a medium effect size (0.63). There was not a significant improvement in the CGI or QIDS-SR. Conclusions: The results show a mixed picture the impact ketamine on symptoms of depression in TRD over the course of multiple infusions. The results need to be viewed in the context of clinical outcome data collection: outcome scores are taken prior to treatment and so are at a point when ketamine is not having an active effect. The findings can inform the availability of ketamine infusion as a treatment option for TRD where treatment adhering to national guidelines has not succeeded. A qualitative investigation of the experience of people receiving ketamine would provide further insights.
Cite this paper: Griffiths, C. , O’Neill-Kerr, A. , De Vai, R. , Sore, T. and Silva, K. (2019) Ketamine Infusion (KI) in Treatment Resistant Depression (TRD): Retrospective Clinical Data Analysis. Open Journal of Depression, 8, 59-70. doi: 10.4236/ojd.2019.83007.
References

[1]   Andrade, C. (2018). Ketamine as Anaesthesia for ECT: Is There Room to Improve a Gold Standard Treatment? The British Journal of Psychiatry, 212, 129-130.
https://doi.org/10.1192/bjp.2017.15

[2]   Antunes, P. B., & Fleck, M. P. (2009). Clinical Outcomes and Quality of Life in Patients Submitted to Electroconvulsive Therapy. The Journal of ECT, 25, 182-185.
https://doi.org/10.1097/YCT.0b013e318190b2a9

[3]   APA (2000). Diagnostic and Statistical Manual of Mental Disorders (p. 4). Washington DC: American Psychiatric Association.

[4]   Beck, A. T., & Alford, B. A. (2009). Depression: Causes and Treatment. Philadelphia, PA: University of Pennsylvania Press.

[5]   Berlim, M. T., & Turecki, G. (2007). What Is the Meaning of Treatment Resistant/Refractory Major Depression (TRD)? A Systematic Review of Current Randomized Trials. European Neuropsychopharmacology, 17, 696-707.
https://doi.org/10.1016/j.euroneuro.2007.03.009

[6]   Best, S. R. D. (2015). Combined Ketamine and Transcranial Magnetic Stimulation for Treatment Resistant Depression in the Context of Chronic OCD: A Case Report. Neuropsychiatric Electrophysiology, 1, 2.
https://doi.org/10.1186/s40810-015-0003-y

[7]   Best, S., & Pavel, D. G. (2017). Combined Transcranial Magnetic Stimulation and Ketamine for Treatment of Refractory Mood Disorder, Anxiety, and Pain: A Case Study. Current Neurobiology, 8, 1-4.

[8]   Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Drevets, W. C. et al. (2018). Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. American Journal of Psychiatry, 175, 620-630.
https://doi.org/10.1176/appi.ajp.2018.17060720

[9]   Coyle, C. M., & Laws, K. R. (2015). The Use of Ketamine as an Antidepressant: A Systematic Review and Meta-Analysis. Human Psychopharmacology: Clinical and Experimental, 30, 152-163.
https://doi.org/10.1002/hup.2475

[10]   Eaton, W. W., Martins, S. S., Nestadt, G., Bienvenu, O. J., Clarke, D., & Alexandre, P. (2008). The Burden of Mental Disorders. Epidemiologic Reviews, 30, 1-14.
https://doi.org/10.1093/epirev/mxn011

[11]   FDA (2019). FDA Approves New Nasal Spray Medication for Treatment-Resistant Depression; Available Only at a Certified Doctor’s Office or Clinic. Food and Drug Administration.
https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified

[12]   Fond, G., Loundou, A., Rabu, C., Macgregor, A., Lançon, C., Brittner, M., Roger, M. et al. (2014). Ketamine Administration in Depressive Disorders: A Systematic Review and Meta-Analysis. Psychopharmacology, 231, 3663-3676.
https://doi.org/10.1007/s00213-014-3664-5

[13]   Fergusson, G. M., Cullen, L. A., Freeman, C. P., & Hendry, J. D. (2004). Electroconvulsive Therapy in Scottish Clinical Practice: A National Audit of Demographics, Standards, and Outcome. The Journal of ECT, 20, 166-173.
https://doi.org/10.1097/00124509-200409000-00008

[14]   Forkmann, T., Scherer, A., Boecker, M., Pawelzik, M., Jostes, R., & Gauggel, S. (2011). The Clinical Global Impression Scale and the Influence of Patient or Staff Perspective on Outcome. BMC Psychiatry, 11, 83.
https://doi.org/10.1186/1471-244X-11-83

[15]   Gould, T. D., Zarate Jr., C. A., & Thompson, S. M. (2019). Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants. Annual Review of Pharmacology and Toxicology, 59, 213-236.
https://doi.org/10.1146/annurev-pharmtox-010617-052811

[16]   Grady, S. E., Marsh, T. A., Tenhouse, A., & Klein, K. (2017). Ketamine for the Treatment of Major Depressive Disorder and Bipolar Depression: A Review of the Literature. Mental Health Clinician, 7, 16-23.
https://doi.org/10.9740/mhc.2017.01.016

[17]   Grammer, G. G., Kuhle, A. R., Clark, C. C., Dretsch, M. N., Williams, K. A., & Cole, J. T. (2015). Severity of Depression Predicts Remission Rates Using Transcranial Magnetic Stimulation. Frontiers in Psychiatry, 6, 114.
https://doi.org/10.3389/fpsyt.2015.00114

[18]   Griffiths, C. A., & Griffiths, L. J. (2014). Recovery and Reliable Change Rates for Patients Scoring Severe on Depression, Anxiety or Impaired Functioning in a Psychological Therapies Service: IAPT. Mental Health Review Journal, 20, 28-35.
https://doi.org/10.1108/MHRJ-06-2014-0022

[19]   Griffiths, C., O’Neill-Kerr, A., Millward, T., & Da Silva, K. (2019). Repetitive Transcranial Magnetic Stimulation (rTMS) for Depression: Outcomes in a United Kingdom (UK) Clinical Practice. International Journal of Psychiatry in Clinical Practice, 23, 122-127.
https://doi.org/10.1080/13651501.2018.1562077

[20]   Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology (pp. 534-537).
https://doi.org/10.1037/e591322011-001

[21]   Hardy, S., Bastick, L., O’Neill-Kerr, A., Sabesan, P., Lankappa, S., & Palaniyappan, L. (2016). Transcranial Magnetic Stimulation in Clinical Practice. BJPsych Advances, 22, 373-379.
https://doi.org/10.1192/apt.bp.115.015206

[22]   Hashimoto, K. (2009). Emerging Role of Glutamate in the Pathophysiology of Major Depressive Disorder. Brain Research Reviews, 61, 105-123.
https://doi.org/10.1016/j.brainresrev.2009.05.005

[23]   Health Quality Ontario (2016). Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Ontario Health Technology Assessment Series, 16, 1.

[24]   Jackson-Koku, G. (2016). Beck Depression Inventory. Occupational Medicine, 66, 174-175.
https://doi.org/10.1093/occmed/kqv087

[25]   Janicak, P. G., & Dokucu, M. E. (2015). Transcranial Magnetic Stimulation for the Treatment of Major Depression. Neuropsychiatric Disease and Treatment, 11, 1549.
https://doi.org/10.2147/NDT.S67477

[26]   Kishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., & Correll, C. U. (2016). Single-Dose Infusion Ketamine and Non-Ketamine N-methyl-d-aspartate Receptor Antagonists for Unipolar and Bipolar Depression: A Meta-Analysis of Efficacy, Safety and Time Trajectories. Psychological Medicine, 46, 1459-1472.
https://doi.org/10.1017/S0033291716000064

[27]   Kito, S., Fujita, K., & Koga, Y. (2008). Regional Cerebral Blood Flow Changes after Low-Frequency Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex in Treatment-Resistant Depression. Neuropsychobiology, 58, 29-36.
https://doi.org/10.1159/000154477

[28]   Lazzaro, V. D., Oliviero, A., Profice, P., Pennisi, M. A., Pilato, F., Zito, G., Tonali, P. A. et al. (2003). Ketamine Increases Human Motor Cortex Excitability to Transcranial Magnetic Stimulation. The Journal of Physiology, 547, 485-496.
https://doi.org/10.1113/jphysiol.2002.030486

[29]   Leuchter, A. F., Espinoza, R., Suthana, N., Hunter, A., & Cook, I. A. (2017). Synergistic Effects of Ketamine and Theta Burst Stimulation in the Treatment of Major Depressive Disorder (MDD). Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation, 10, 492.
https://doi.org/10.1016/j.brs.2017.01.438

[30]   López-Díaz, á., Murillo-Izquierdo, M., & Moreno-Mellado, E. (2019). Off-Label Use of Ketamine for Treatment-Resistant Depression in Clinical Practice: European Perspective. The British Journal of Psychiatry, 215, 447-448.
https://doi.org/10.1192/bjp.2019.102

[31]   Mohn, C., & Rund, B. R. (2016). Significantly Improved Neurocognitive Function in Major Depressive Disorders 6 Weeks after ECT. Journal of Affective Disorders, 202, 10-15.
https://doi.org/10.1016/j.jad.2016.03.062

[32]   Morgan, C. J., Curran, H. V., & Independent Scientific Committee on Drugs (ISCD) (2012). Ketamine Use: A Review. Addiction, 107, 27-38.
https://doi.org/10.1111/j.1360-0443.2011.03576.x

[33]   Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I. (2014). A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996-2013. Psychiatric Services, 65, 977-987.
https://doi.org/10.1176/appi.ps.201300059

[34]   Nemeroff, C. B. (2007). Prevalence and Management of Treatment-Resistant Depression. Journal of Clinical Psychiatry, 68, 17.

[35]   NHFT (2019). Protocol for Electroconvulsive Therapy (ECT) Treatment Centre within Northamptonshire Healthcare Trust.
https://www.nhft.nhs.uk/download.cfm?doc=docm93jijm4n1809

[36]   NICE (2015). Repetitive Transcranial Magnetic Stimulation for Depression.
https://www.nice.org.uk/guidance/ipg542

[37]   Pittenger, C., & Duman, R. S. (2008). Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms. Neuropsychopharmacology, 33, 88.
https://doi.org/10.1038/sj.npp.1301574

[38]   Reeves, G. M., Rohan, K. J., Langenberg, P., Snitker, S., & Postolache, T. T. (2012). Validation of BDI-II Response and Remission Cut-Points for Assessment of Seasonal Affective Disorder Patients. Journal of Affective Disorders, 138, 123.
https://doi.org/10.1016/j.jad.2011.12.003

[39]   Riedel, M., Möller, H. J., Obermeier, M., Schennach-Wolff, R., Bauer, M., Adli, M., Bender, W. et al. (2010). Response and Remission Criteria in Major Depression: A Validation of Current Practice. Journal of Psychiatric Research, 44, 1063-1068.
https://doi.org/10.1016/j.jpsychires.2010.03.006

[40]   Royal College of Psychiatrists (2017). Statement on Ketamine to Treat Depression. London: Royal College of Psychiatrists, Committee on ECT and Related.

[41]   Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., McGrath, P. J. et al. (2006). Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR* D Report. American Journal of Psychiatry, 163, 1905-1917.
https://doi.org/10.1176/ajp.2006.163.11.1905

[42]   Sanacora, G., Treccani, G., & Popoli, M. (2012). Towards a Glutamate Hypothesis of Depression: An Emerging Frontier of Neuropsychopharmacology for Mood Disorders. Neuropharmacology, 62, 63-77.
https://doi.org/10.1016/j.neuropharm.2011.07.036

[43]   Singh, I., Morgan, C., Curran, V., Nutt, D., Schlag, A., & McShane, R. (2017). Ketamine Treatment for Depression: Opportunities for Clinical Innovation and Ethical Foresight. The Lancet Psychiatry, 4, 419-426.
https://doi.org/10.1016/S2215-0366(17)30102-5

[44]   Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Zohar, J. et al. (2007). Clinical Factors Associated with Treatment Resistance in Major Depressive Disorder: Results from a European Multicenter Study. Journal of Clinical Psychiatry, 68, 1062-1070.
https://doi.org/10.4088/JCP.v68n0713

[45]   Tardito, D., Perez, J., Tiraboschi, E., Musazzi, L., Racagni, G., & Popoli, M. (2006). Signaling Pathways Regulating Gene Expression, Neuroplasticity, and Neurotrophic Mechanisms in the Action of Antidepressants: A Critical Overview. Pharmacological Reviews, 58, 115-134.
https://doi.org/10.1124/pr.58.1.7

[46]   Tsuzuki, D., Watanabe, H., Dan, I., & Taga, G. (2016). MinR 10/20 System: Quantitative and Reproducible Cranial Landmark Setting Method for MRI Based on Minimum Initial Reference Points. Journal of Neuroscience Methods, 264, 86-93.
https://doi.org/10.1016/j.jneumeth.2016.02.024

[47]   The UK ECT Review Group (2003). Efficacy and Safety of Electroconvulsive Therapy in Depressive Disorders: A Systematic Review and Meta-Analysis. The Lancet, 361, 799-808.
https://doi.org/10.1016/S0140-6736(03)12705-5

[48]   WHO (2017). Depression Fact Sheet.
http://www.who.int/mediacentre/factsheets/fs369/en

[49]   Xu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., Mitchell, P. B. et al. (2015). Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: A Systematic Review and Meta-Analysis. International Journal of Neuropsychopharmacology, 19, pyv124.
https://doi.org/10.1093/ijnp/pyv124

 
 
Top